Skip to main content
Journal cover image

PO23-755 EZETIMIBE/SIMVASTATIN MORE FAVORABLY INFLUENCES LIPOPROTEIN/APOLIPOPROTEIN RATIOS THAN ATORVASTATIN MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES

Publication ,  Conference
Guyton, JR; Goldberg, RB; Mazzone, T; Weinstock, RS; Polis, A; Rosenberg, E; Edwards, P; Tershakovec, AM
Published in: Atherosclerosis Supplements
June 2007

Duke Scholars

Published In

Atherosclerosis Supplements

DOI

ISSN

1567-5688

Publication Date

June 2007

Volume

8

Issue

1

Start / End Page

201 / 201

Publisher

Elsevier BV

Related Subject Headings

  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Guyton, J. R., Goldberg, R. B., Mazzone, T., Weinstock, R. S., Polis, A., Rosenberg, E., … Tershakovec, A. M. (2007). PO23-755 EZETIMIBE/SIMVASTATIN MORE FAVORABLY INFLUENCES LIPOPROTEIN/APOLIPOPROTEIN RATIOS THAN ATORVASTATIN MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES. In Atherosclerosis Supplements (Vol. 8, pp. 201–201). Elsevier BV. https://doi.org/10.1016/s1567-5688(07)71765-8
Guyton, J. R., R. B. Goldberg, T. Mazzone, R. S. Weinstock, A. Polis, E. Rosenberg, P. Edwards, and A. M. Tershakovec. “PO23-755 EZETIMIBE/SIMVASTATIN MORE FAVORABLY INFLUENCES LIPOPROTEIN/APOLIPOPROTEIN RATIOS THAN ATORVASTATIN MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES.” In Atherosclerosis Supplements, 8:201–201. Elsevier BV, 2007. https://doi.org/10.1016/s1567-5688(07)71765-8.
Guyton JR, Goldberg RB, Mazzone T, Weinstock RS, Polis A, Rosenberg E, et al. PO23-755 EZETIMIBE/SIMVASTATIN MORE FAVORABLY INFLUENCES LIPOPROTEIN/APOLIPOPROTEIN RATIOS THAN ATORVASTATIN MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES. In: Atherosclerosis Supplements. Elsevier BV; 2007. p. 201–201.
Guyton, J. R., et al. “PO23-755 EZETIMIBE/SIMVASTATIN MORE FAVORABLY INFLUENCES LIPOPROTEIN/APOLIPOPROTEIN RATIOS THAN ATORVASTATIN MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES.” Atherosclerosis Supplements, vol. 8, no. 1, Elsevier BV, 2007, pp. 201–201. Crossref, doi:10.1016/s1567-5688(07)71765-8.
Guyton JR, Goldberg RB, Mazzone T, Weinstock RS, Polis A, Rosenberg E, Edwards P, Tershakovec AM. PO23-755 EZETIMIBE/SIMVASTATIN MORE FAVORABLY INFLUENCES LIPOPROTEIN/APOLIPOPROTEIN RATIOS THAN ATORVASTATIN MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES. Atherosclerosis Supplements. Elsevier BV; 2007. p. 201–201.
Journal cover image

Published In

Atherosclerosis Supplements

DOI

ISSN

1567-5688

Publication Date

June 2007

Volume

8

Issue

1

Start / End Page

201 / 201

Publisher

Elsevier BV

Related Subject Headings

  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology